Brown Advisory Inc. Has $71.70 Million Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

Brown Advisory Inc. increased its position in shares of SI-BONE, Inc. (NASDAQ:SIBNGet Rating) by 2.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,172,975 shares of the company’s stock after purchasing an additional 82,189 shares during the quarter. Brown Advisory Inc. owned approximately 9.36% of SI-BONE worth $71,703,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. IndexIQ Advisors LLC acquired a new stake in shares of SI-BONE during the 1st quarter worth about $429,000. Assenagon Asset Management S.A. grew its holdings in SI-BONE by 64.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 60,006 shares of the company’s stock worth $1,356,000 after acquiring an additional 23,584 shares during the last quarter. Diversified Trust Co grew its holdings in SI-BONE by 8.4% during the 1st quarter. Diversified Trust Co now owns 10,950 shares of the company’s stock worth $247,000 after acquiring an additional 850 shares during the last quarter. Silvercrest Asset Management Group LLC grew its holdings in SI-BONE by 17.1% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 342,336 shares of the company’s stock worth $7,603,000 after acquiring an additional 49,880 shares during the last quarter. Finally, Select Equity Group L.P. grew its holdings in SI-BONE by 4.3% during the 4th quarter. Select Equity Group L.P. now owns 42,056 shares of the company’s stock worth $934,000 after acquiring an additional 1,727 shares during the last quarter. Institutional investors and hedge funds own 99.36% of the company’s stock.

SI-BONE Stock Performance

SI-BONE stock opened at $16.69 on Friday. The company’s 50 day simple moving average is $14.02 and its 200 day simple moving average is $17.53. SI-BONE, Inc. has a fifty-two week low of $11.89 and a fifty-two week high of $25.96. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.44 and a quick ratio of 9.48.

SI-BONE (NASDAQ:SIBNGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.09). SI-BONE had a negative return on equity of 44.52% and a negative net margin of 67.00%. The firm had revenue of $22.44 million for the quarter, compared to the consensus estimate of $22.37 million. During the same period in the previous year, the business earned ($0.37) EPS. As a group, equities analysts anticipate that SI-BONE, Inc. will post -1.93 EPS for the current fiscal year.

Insider Buying and Selling

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,466 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $12.58, for a total transaction of $43,602.28. Following the sale, the senior vice president now directly owns 123,581 shares in the company, valued at approximately $1,554,648.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other SI-BONE news, CEO Laura Francis sold 4,805 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $12.58, for a total transaction of $60,446.90. Following the sale, the chief executive officer now directly owns 330,973 shares in the company, valued at approximately $4,163,640.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Pisetsky sold 3,466 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $12.58, for a total transaction of $43,602.28. Following the sale, the senior vice president now owns 123,581 shares in the company, valued at $1,554,648.98. The disclosure for this sale can be found here. Insiders have sold 28,439 shares of company stock valued at $365,329 in the last 90 days. 5.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SIBN has been the topic of a number of research analyst reports. Truist Financial decreased their price objective on shares of SI-BONE to $17.00 in a report on Friday, July 22nd. Canaccord Genuity Group decreased their price objective on shares of SI-BONE from $32.00 to $25.00 in a report on Tuesday, May 10th. Morgan Stanley reduced their target price on shares of SI-BONE from $22.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, July 15th. Finally, JMP Securities reaffirmed a “buy” rating and issued a $36.00 target price on shares of SI-BONE in a research note on Wednesday, June 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $28.29.

SI-BONE Profile

(Get Rating)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

Read More

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.